Ariceum Hopes To One-Up Novartis Drug With Potent Radiopharmaceutical Focus

 
• By Ayisha Sharma

Emerging Company Profile: The private German biotech Ariceum has just launched with a €25m financing to advance its lead radioligand candidate, satoreotide, into Phase I development and hopes its antagonist approach could give Novartis’s Lutathera a run for its money.    

Emerging Compan Profile: Ariceum Therapeutics
Ariceum Hopes To Revolutionize The Role of Radioactive Compounds For Cancer • Source: Shutterstock

More from Emerging Company Profiles

More from Start-Ups & SMEs